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Parkinson disease (PD) is the second most common neurodegenerative disease after Alzheimer 
disease, and current demographic trends show an overall life-time risk close to 4% and predict a 
doubling of case numbers by 2030 (Schapira, 2013). PD is characterised by a variety of symptoms 
such as resting tremor, bradykinesia, rigidity and postural instability (Langston, 2002). These 
symptoms are attributed to the reduction in striatal dopamine levels, which are due to progressive 
degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (Moore et al., 
2005; Wakamatsu et al., 2008). Several risk factors have been identified, and type 2 diabetes is one 
of these (Hu et al., 2007; Schernhammer et al., 2011; Sun et al., 2012; Wahlqvist et al., 2012). 
Previous studies have documented the importance of insulin signaling in the brain (Freiherr et al., 
2013; Ghasemi et al., 2013; van der Heide et al., 2006), and observed that insulin signaling is 
compromised in the brains of patients with PD (Aviles-Olmos et al., 2013b; Moroo et al., 1994; 
Morris et al., 2011). Analogues of incretin hormones have been developed to improve insulin 
signaling in type II diabetes (Campbell and Drucker, 2013; Holst, 2004). The main incretin 
hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP) (Baggio and Drucker, 2007; Campbell and Drucker, 2013; Doyle and Egan, 2003). We and 
others have shown that GLP-1 and GIP receptor agonists have shown protective effects in animal 
models of Alzheimer’s disease (Bomfim et al., 2012; Duffy and Holscher, 2013; Faivre and 
Holscher, 2013a, b; Li et al., 2010; McClean et al., 2011), and clinical trials have started (Hölscher, 
2016) with first positive results having been published (Gejl et al., 2016). Importantly, previous 
investigations found that GLP-1 receptor agonists also showed good neuroprotective effects in 
different animal models of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Li et al., 2009; Liu et 
al., 2015a; Zhang et al., 2015) and showed good effects in a pilot study in PD patients (Aviles-
Olmos et al., 2013a; Aviles-Olmos et al., 2014). We have shown good protective effects with GLP-
1 and also GIP mimetics in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP) mouse 
model of PD, demonstrating that both receptor pathways show promise to ameliorate disease 
progression in PD (Li et al., 2015b; Liu et al., 2015a; Liu et al., 2015b; Zhang et al., 2015). The 
GLP-1 mimetic exendin-4 furthermore showed good effects in the 6-OHDA lesion rat model of PD 
(Bertilsson et al., 2008; Harkavyi et al., 2008) 
Novel dual GLP-1/GIP receptor agonists have been developed to treat type II diabetes and show 
superior effects to single GLP-1 receptor agonists (Finan et al., 2013). We tested one of these dual 
agonists (DA-JC1) in the rotenone cell culture model of PD and found that it was protective at a far 
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lower dose than single GLP-1 or GIP analogues (Jalewa et al., 2016). We furthermore tested the 
effects of this potent GLP-1/GIP receptor agonist in the MPTP mouse model of PD. We found that 
DA-JC1 protected mice from the toxic effects of MPTP and reduced loss of motor control, 
enhanced numbers of TH positive neurons in the substantia nigra, reduced chronic inflammation 
and apoptotic signaling while enhancing levels of BDNF, a growth factor that protects synapses, 
and PI3k activity (Cao et al., 2016; Ji et al., 2015). However, animal models of PD do not 
recapitulate all parameters of PD, and results from these models do not always translate to the clinic 
(Bove and Perier, 2012; Morin et al., 2014). We therefore tested the DA-JC1 drug in the unilateral 
6-OHDA lesion rat model of PD to further investigate if this dual agonist has protective effects in 




Materials and Methods 
 
Animals 
All animal experiments and procedures were carried out in accordance with the animal handling 
laws and protocols/procedures approved by the Home Office, London, UK. We used Sprague 
Dawley male rats in this study that weighed approximately 350-450 gm. The animals were single 
housed in Individually ventilated cages (IVC’s) and had a reverse 12-h light-on-light-off cycle with 
food and water provided ad libitum. The temperature of the room was set to 21+ 2 C°. The weight 
and food intake of animals was registered weekly. 
 
Peptide 
The dual agonist DA-JC1 (Peptide Purity: 95.77%) was obtained from the Shanghai Qiangyao 
Biological Technology (Shanghai, China). The purity of the peptide was confirmed by reversed-
phase HPLC and characterised using matrix assisted laser desorption/ionisation time of flight 
(MALDI-TOF) mass spectrometry.  




X = aminoisobutyric acid; K = Lys-gE-C16 acyl 
 
 
Animal Surgery  
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To increase the selectivity of 6-OHDA towards Dopaminergic neurons, the rats were injected with 
one intraperitoneal (i.p.) injection with pargyline (5 mg/kg; monoamine oxidase inhibitor) and 
desipramine (25 mg/kg; noradrenaline uptake inhibitor) 30 min before surgery. The animals were 
anaesthetised via i.p. injection of Ketamine (100mg/kg body weight) and Xylazine (10mg/kg body 
weight) and fixed into a stereotaxic frame (WPI International) using ear bars and nose clamp. 
During the surgery the animal was placed on a heat pad to maintain its body temperature. The skull 
was shaven and cleaned using alcohol wipes and Betadine Providone Iodine antiseptic solution. A 
sterile scalpel was used to make a 2 cm incision to expose the skull, followed by measuring and 
marking the coordinates relative to bregma and drilling a hole at the preferred lesioning site. A 
fresh vial of 6-OHDA (2mg/ml in 0.01% Ascorbic acid prepared in saline and protected from light 
and stored at -20 deg C) was used for every lesion and 5µl of this solution was injected at a speed of 
1µl/min into the right medial forebrain bundle  
 (MFB) (Anteroposterior: -2.2, Lateral: -1.5, Dorsoventral: -8.0) using a 10µL Neuro Syringe 
(Hamilton, Germany) with a 33-gauge needle. In the control group, sham saline was injected with 
0.01% Ascorbic acid. The syringe was left in place for 5 min after injection and gently retracted 
back. The hole in the skull was blocked up using sterile bone-wax (Stoelting, Germany) and the 
wound closed using 2-3 sutures (Ethilon Nylon sutures, Ethicon). 4% Lidocaine cream was applied 
near the incision site on the skull followed by Metacam sub-cutaneous pain relief. The rats were 
placed on a temperature-regulated heated blanket to maintain their body temperature post-recovery 
and 1ml of sterile water was administered i.p. as soon as the animal showed signs of recovery. After 
2-3 hours of recovery from anaesthesia, when mobile and conscious, the animal were returned in 
their home cage and placed in the IVC rack. The animals with 6-OHDA lesion showed a preference 
towards the ipsilateral side during recovery. Post-recovery, the animals were fed with apples and 
soft food for 3 days and their body-weights were recorde and fluid intake was recorded.  
 
Treatment with DA-JC1	Starting	6	days	after	the	6-OHDA	lesion,	DA-JC1	was	administered	at	25nmol/kg	ip	once-daily	for	6	weeks	(see	Fig.	1).	 
 
Apomorphine induced circling test 
After 6 weeks of surgery the rats received subcutaneous injection of Apomorphine (Tocris), 
(0.05mg/kg body weight). 10min after injection, the rats were placed in a clean open-field arena and 
their activity was recorded by a computerised tracking system (Biosignals, New York) for 40 
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minutes. The total number of contralateral (opposite the lesioned side) rotations was counted by 
individuals blind to the experiment.  
 
Amphetamine induced circling test   
After 10-12 days of surgery the rats received Methamphetamine hydrochloride (Sigma), i.p. 
(3mg/kg body weight). After 30min of injection, the rats were placed in a clean open-field arena 
and their activity was recorded by a computerised tracking system (Biosignals, New York) for 10 
minutes. The total number of ipsiversive (towards the lesioned side) rotations was counted by 
individuals blind to the experiment.  
 
Rotarod Test  
Balance and motor coordination was assessed using the Rotarod test (IITC, WPI, UK). Rats were 
submitted to the rotarod test in the 2nd and 4th week after surgery. Rats were trained on the rotarod 
twice a day (3 hour inter-trial period) for 3 consecutive days, with the rod accelerating at 10 rpm for 
300sec maximum. For the test, the rats were placed on the rotarod that accelerated from 5 to 20 rpm 
in 20sec and also at 5-45rpm in 200 sec. The latency to fall off and the distance travelled was 
recorded automatically for a period up to 200sec. 
 
Open Field Test 
5 weeks following surgery, the rats were placed in a 150cm diameter, clean, open and well lit arena. 
The animals were exposed to the arena on two consecutive days for 5 minutes before recording 
their movement for 10 min on the third day. The animals were recorded by a digital camera. The 
video was analysed off-line using Ethovision software, Noldus. The arena was cleaned and dried 
thoroughly before each trial. 
 
Dissection and striatal tissue homogenisation 
Rats were deeply anaesthetised with Ketamine and Xylazine, followed by cervical dislocation. 
After perfusion with 4% PFA solution via the heart, the brains were removed and striata dissected 
and snap frozen in liquid nitrogen for storage. The striatum was homogenised in phosphate buffered 
saline (PBS) with protease inhibitor (Roche). For 100mg tissue, 1ml of ice-cold homogenisation 
buffer was used and later stored at -20ºC overnight. Total protein was extracted by centrifugation at 
10,000rpm for 10min and the supernatant collected. Quick start Bradford protein assay reagent 
(Biorad) was used to quantify the protein concentration in the supernatant. 
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Striatal Dopamine quantification 
The assay was performed in a 96-well plate as per the manufacturer’s instructions of the rat 
dopamine ELISA kit (CUSABIO, USA). Briefly, striatal lysates were diluted 1:2 in the sample 
diluent and the plates were incubated for 2 hours at 37ºC. After removing the liquid from each well, 
100µl of biotin conjugated antibody against dopamine was added to each well and the plate 
incubated for 1 hour at 37ºC. Each well was aspirated and washed with the wash buffer three times 
followed by addition of 100µl HRP-avidin antibody and incubated at 37ºC for 1 hour. After 
washing  5 times, 90µl of TMB substrate was added and the plate incubated for 30min at 37ºC, 
protected from light. Finally, 50µl of stop solution was added and after gentle mixing, the plate was 
read at 450nm. The dopamine concentrations were calculated from the standard curve and 
normalised against total protein. 
 
Western blotting 
Lysate containing 2µg of protein was separated on 20-well 4-12% gradient Bis-Tris midi gel with 
Novex pre-stained marker (Invitrogen) and electrophoresed in running buffer at 180mV for 90min 
followed by transfer to polyvinylidene difluoride (PVDF) membrane using iBlot® 2 Gel Transfer 
Device. Following protein transfer, the membrane was washed in 1X TBS-T (tris-buffered saline 
with 0.05% Tween-20, pH 8) and blocked in 5% skimmed milk for 1hr at 25°C. The membrane was 
then incubated with anti-pAkt (Ser473) (1:1000) at 4°C overnight and after three washes (5min 
each) in TBS-T further incubated with 1:2000 horseradish peroxidase-conjugated anti-rabbit IgG. 
The protein bands were visualized by Amersham ECL Prime western blotting detection reagent 
according to the manufacturer’s instructions. ChemiDoc MP Imaging System with Image Lab 
software (BIO-RAD) was used to image chemiluminescent bands and perform the analysis of each 
band intensity. Image LabTM software controls image capture and optimiszation and produces 
reports. Beta-actin was used as loading control and relative peak intensity of each marker band 
analysed on Mac Numbers after normalizing with loading control. To reprobe, the membranes were 
incubated with Restore stripping buffer (Thermo Scientific, UK) with some agitation for 15min at 
RT followed by 3 washes in TBS-T for 5min each. The membranes were checked with 
chemiluminescent detection preceding incubation in another primary antibody of interest.  
 
Perfusion and Immunofluorescence 
Eight weeks post surgery, rats were anaesthetised with Ketamine and Xylazine and perfused 
transcardially with 0.1 M PBS (pH 7.4) buffer followed by ice-cold 4% paraformaldehyde in PBS. 
The brains were removed and fixed in 4% paraformaldehyde for at least a week and cryoprotected 
A novel dual agonist is neuroprotective	
	 8	
in a 30% sucrose solution in PBS until the brains sank to the bottom. Brains were then snap frozen 
using Envirofreez, and coronal sections of 40 µm thickness were cut using a Leica cryostat. 
Substantia nigra sections were cut according to the rat brain atlas by George Paxinos and Charles 
Watson (sixth edition). Sections were chosen according to the stereological rules, with the first 
section taken at random and every seventh section afterward. At least 8-10 sections were taken per 
immunostaining experiment. 
Immunofluorescence (IF) staining for Tyrosine Hydroxylase (TH) immunopositive neurons was 
performed on the Substantia nigra (SNpc) 40 µm free-floating sections of the following 3 groups: 1. 
sham saline, 2. 6-OHDA saline and 3. 6-OHDA lesioned, GLP-1/GIP dual agonist treated group. 
Sections were permeabilised in 0.3% Triton-X 100 in PBS followed by blocking in 5% donkey 
serum. Staining involved incubating the sections with NB300-110 Sheep Polyclonal Tyrosine 
Hydroxylase primary antibody (Novus biologicals, 1:500), overnight at 4ºC. Next day, after 3 
washes in PBS-T, sections were incubated at room temperature for 1hr with donkey anti-Sheep IgG 
(H+L) secondary antibody, Alexa Fluor® 488 conjugate (Invitrogen) (1:1000). Sections were 
cover-slipped with Vectashield mounting medium (Vector laboratories) and sealed with nail polish. 
Imaging was done on a Zeiss LSM510 Meta Laser Scanning confocal microscope at 488nm 
wavelength in tiling mode, 3 x 3 tile, 15% overlap.  
The numbers of TH-immunospositive neurons in substantial nigra were quantified by applying 2D 
stereology rules (Bondolfi et al., 2002) by randomly choosing the first section and every third after 
that. An unbiased dissector was applied randomly to images (x:573.67µm, y:573.67µm.) with 5 




Statistical analysis was done with a two-way ANOVA or one-way ANOVA followed by 
Bonferroni’s Multiple Comparison post-hoc test using the statistics program Prism (Graphpad 





Body weight and food consumption of rats 
As GLP-1 analogues can have a weight reducing effect in obese animals and humans (Rodriquez de 
Fonseca et al., 2000; Wadden et al., 2013), we monitored the weight and food intake. There was no 
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difference between groups in a three level, two-way ANOVA as shown in fig. 2. N=8 per group. 
 
Amphetamine induced circling test 
DA-JC-1 treatment decreased Amphetamine-induced rotations when measured 5 weeks post-lesion. 
The amphetamine-circling test showed a significant decrease in the ipsilateral rotations of 6-OHDA 
exposed rats that received DA-JC1 compared with the saline injected 6-OHDA lesioned rats. A 
34% decrease (p<0.05: One-way ANOVA with Bonferroni post-hoc test) in the number of 
Amphetamine induced rotations in the DA-JC1 treated group was observed after 4weeks of 
treatment. A 33.3% decrease (p<0.05) in the number of Amphetamine induced rotations in the DA-
JC1 treated group was observed when compared to saline treated 6-OHDA lesioned group. An 
increase of 28% (non-significant) in the number of Amphetamine induced rotations was observed 
from 1st to 5th week of saline treated group. One-way ANOVA followed by Bonferroni’s Multiple 
Comparison post hoc test, N=8 per group, see fig. 3A. 
 
Apomorphine induced contralateral rotation test 
Six weeks post-surgery the rats received subcutaneous injection of apomorphine, (0.05mg/kg body 
weight). Contralateral rotations were tracked and quantified. The DA-JC1 treatment decreased 
apomorphine-induced rotations by 89.4% (p<0.001) in the contralateral rotations exhibited by the 
6-OHDA exposed rats that received DA-JC1 compared with the saline treated ones. One-way 
ANOVA followed by Bonferroni’s Multiple Comparison post hoc test, N=8 per group, see fig. 3B. 
 
Rotarod test 
5-45rpm in 200 sec 
DA-JC1 treatment improved balance and coordination when tested 2 weeks post-lesion. A 
significant improvement exhibited in the speed, time and distance by the 6-OHDA lesioned, treated 
with DA-JC1 group when compared with the saline treated 6-OHDA group. An increase of 17% 
(p<0.01) and 46% (p<0.01) was observed in the maximum speed attained on the Rotarod after 
2weeks and 4 weeks post-lesion, respectively. An increase of 21% (p<0.01) and 76% (p<0.01) was 
observed in the total time on the Rotarod before falling after 2weeks and 4 weeks post-lesion, 
respectively. A 34% increase (p<0.05) and a 2-fold increase was observed in the total distance 
travelled on the Rotarod after 2weeks and 4 weeks post-lesion, respectively, see fig. 4 top. 
 
5 to 20rpm in 20 sec 
The DA-JC1 treatment improved balance and coordination at a slower setting. An increase of 6.3% 
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(p<0.05) and 13.5% (p<0.05) was observed in the maximum speed attained on the Rotarod after 2 
weeks and 4 weeks post-lesion, respectively. An increase of 3-fold (p<0.0001) and 4-fold (p<0.01) 
was observed in the total time on the Rotarod before falling after 2 weeks and 4 weeks, 
respectively. A 4-fold increase (p<0.0001) and a 5-fold (p<0.001) increase was observed in the total 
distance travelled on the Rotarod after 2 weeks and 4 weeks, respectively. One-way ANOVA 
followed by Bonferroni’s Multiple Comparison post hoc test, N=8 per group, see fig. 4 bottom. 
 
Open field test 
Five weeks post-surgery, animals were put into a 15cm diameter open field and tracked. The 
number of grooming episodes was significantly reduced after the 6-OHDA lesion (p<0.05 
compared to sham control) and normalised to control levels by DA-JC1 (p<0.05 compared to 6-
OHDA lesion group). The number of rearings was not affected by the 6-OHDA lesion. The area 
covered when traveling was much reduced by 6-OHDA lesion (p<0.05 compared to sham control) 
and normalized to control levels by DA-JC1 (p<0.05 compared to the 6-OHDA lesion group). 
Sample tracks are shown and a ‘heat map’ representation of overall location distribution which 
demonstrate that overall motor activity is greatly affected by 6-OHDA lesion is normalised by DA-




In the immunohistochemical assessment of TH positive neurons in the substantia nigra, it was 
found that 6-OHDA lesion much reduced the numbers of dopaminergic neurons obtained by 2D 
stereological analysis in the 6-OHDA injected hemisphere (p<0.001 compared to sham control). 
There was a 58% decrease in number of TH + neurons in the 6-OHDA saline treated group and 
DA-JC1 increases the number by 37%. There was no difference between the sham control group 
and the 6-OHDA DA-JC1 treated group. In contrast, there were no differences in neuronal numbers 
when assessing the contralateral non-lesioned hemisphere. When analysing astrogliosis (GFAP 
expression), it was found that the 6-OHDA lesion induced robust chronic inflammation (p<0.0001 
compared to sham saline). DA-JC1 reduced the inflammation (p<0.01 compared to sham saline and 
p<0.05 compared to 6-OHDA saline). One-way ANOVA followed by Bonferroni’s Multiple 
Comparison post hoc test; N=5 per group, see fig 6. 
 
Western blot 
Analysing the levels of activated Akt compared to total Akt, it was found the 6-OHDA had no 
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effect on the activation of this growth factor signaling kinase. DA-JC1 treatment increased the 
levels, though (p<0.01 compared to 6-OHDA and p<0.001 compared to sham control). CREB 
activation was much enhanced by DA-JC1 (p<0.001 compared to 6-OHDA and sham control). 
Importantly, the levels of the growth factor GDNF were much enhanced by DA-JC1 (p<0.01 
compared to 6-OHDA and p<0.05 compared to sham control). The levels of the autophagy 
biomarker beclin1 were also enhanced by DA-JC1 (p<0.05 compared to 6-OHDA and sham 
control).  One-way ANOVA followed by Bonferroni’s Multiple Comparison post hoc test; N=5 per 
group, see fig. 7. 
 
Dopamine levels in the basal ganglia 
When analysing the dopamine content of basal ganglia tissue by ELISA, it was found that the 6-
OHDA injection significantly reduced the levels (p<0.0001 compared to sham controls). Treatment 
of lesioned animals with DA-JC1 increased the dopamine levels compared to 6-OHDA saline 






The results demonstrate that the novel GLP-1/GIP dual receptor agonist DA-JC1 has 
Neuroprotective properties in the 6-OHDA lesion rat model. The 6-OHDA unilateral lesion induced 
circling behaviour which was emphasised by apomorphine or amphetamine by modulating 
dopaminergic transmission. DA-JC1 much reduced circling behaviour, indicating that dopaminergic 
transmission was improved by the drug. Similar observations were made in the Rotarod and the 
open field tests where performance was improved by DA-JC1. The histology confirmed that DA-
JC1 protected dopaminergic neurons from 6-OHDA toxicity. Furthermore, the levels of dopamine 
measured in the basal ganglia were much reduced by 6-OHDA, and nearly normalised by DA-JC1 
treatment. DA-JC1 treatment also enhanced the growth-factor signaling associated kinase Akt in 6-
OHDA treated rats. Akt signaling activates neuroprotective cellular processes and gene expression 
in PD, and gene variations are a risk factor for PD (Xiromerisiou et al., 2008). We have previously 
shown that Akt was also activated by GLP-1 receptor agonists in the MPTP mouse model of PD 
(Liu et al., 2015b) and by the DA-JC1 (Ji et al., 2015). Activation of CREB, a key regulator of gene 
expression, also contributes to neuroprotection (Li et al., 2015b; Sharma et al., 2013). The growth 
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factor Glial-Derived Neurotrophic Factor (GDNF) was expressed at a higher level, which may 
explain the protection of dopaminergic neurons. GDNF has been identified as the key growth factor 
for dopaminergic neurons which enhances cell repair and regeneration (Allen et al., 2013; Broome 
et al., 1999). Interestingly, the autophagy biomarker Beclin1 was enhanced by DA-JC1 treatment. 
Autophagy is a key mechanism to eliminate cellular waste and misfolded proteins to protect the cell 
(Jang et al., 2014). It has been shown that autophagy is one of the cellular systems that are impaired 
in PD, and that can enhance neuronal survival (Ghavami et al., 2014; Zhang et al., 2013). We had 
previously shown in an in vitro study that autophagy is activated by GLP-1 and GIP analogues 
(Jalewa et al., 2016), and our findings in the present study confirm that this is also the case in vivo. 
Importantly, chronic astrogliosis was reduced by DA-JC1, which may contribute to the overall 
neuroprotective effects. Chronic inflammation is a key factor in PD disease progression (Tansey 
and Goldberg, 2010). We have previously shown in the MPTP mouse model of PD that astrogliosis 
and microglia activation is reduced by DA-JC1 (Cao et al., 2016), so our findings in the present 
study confirm the anti-inflammatory properties of GLP-1 and GIP. 
In conclusion, the protective results obtained with DA-JC1 in the 6-OHDA rat model of PD mirror 
those we observed in the MPTP mouse model of PD. We observed protection of motor activity in 
the Rotarod and open field, reduced loss of TH positive neurons in the SN, a reduction of chronic 
inflammation in the brain, enhanced BDNF expression, and protection of synapses (Cao et al., 
2016; Ji et al., 2015). It is encouraging that the distinct improvement in key biomarkers of growth 
factor signaling, apoptosis and inflammation are observed in two different PD animal models. We 
furthermore found protective effects of DA-JC1 in a mouse model of stroke (Han et al., 2015). The 
observed protective effects also confirm the neuroprotective effects of the GLP-1 mimetic exendin-
4 in the 6-OHDA rat model as reported by others (Bertilsson et al., 2008; Harkavyi et al., 2008). 
Another study testing the GLP-1 analogue liraglutide did not find neuroprotective effects in the  6-
OHDA rat model (Hansen et al., 2016). This is most likely due to technical differences in the study 
design. For example, in that study, the authors only started to treat the animals with liraglutide 6 
weeks post- 6-OHDA injection in one experiment. It is well known that the dopaminergic neurons 
will have died after 2 weeks post-6-OHDA lesion (Falcone et al., 2015), so no effect of liraglutide 
was to be expected under those conditions.  
We have previously tested a wide range of incretin analogues in the MPTP mouse model of PD. 
When comparing the more effective GLP-1 mimetics liraglutide and lixisenatide with the older 
drug exendin-4, it was found that both liraglutide and lixisenatide showed superior protective 
effects over exendin-4. Motor activity was partly rescued by both drugs, and dopaminergic neurons 
were protected in the substantia nigra. Expression of the dopamine biomarker tyrosine hydroxylase 
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(TH) was also rescued in the liraglutide and lixisenatide treated mice. Pro-apoptotic cell signaling 
was reduced, while growth factor signaling was enhanced by both drugs (Liu et al., 2015a). This 
result was confirmed when testing the GLP-1 analogue (Val8)GLP-1-Glu-PAL, a new version of 
liraglutide with a longer biological half-life (Zhang et al., 2015). Testing the dual GLP-1/glucagon 
receptor agonist D-Ser2-oxyntomodulin furthermore showed similar neuroprotective effects (Liu et 
al., 2015b). When testing the incretin GIP, we found that the long-lasting protease resistant 
analogue D-Ala2-GIP-glu-PAL showed good protective effects. Motor activity was partly rescued, 
and the number of dopaminergic neurons in the substantia nigra was increased. Synapse numbers 
were increased, and the cAMP/PKA/CREB growth factor signaling pathway was activated by D-
Ala2-GIP-glu-PAL (Li et al., 2015b). We and others also found good neuroprotective effects of 
GLP-1 and GIP mimetics in mouse models of Alzheimer’s disease (Cai et al., 2014; Faivre and 
Holscher, 2013b; Li et al., 2010; McClean and Holscher, 2014; Perry and Greig, 2005), and others 
found neuroprotective effects of GLP-1 mimetics in traumatic brain injury (Eakin et al., 2013; Li et 
al., 2015a). These studies demonstrate that both GLP-1 and GIP signaling pathways show 
promising protective effects by activating growth factor signaling pathways, reducing 
inflammation, re-sensitising insulin signaling in the brain and normalising energy utilisation 
(Holscher, 2014). Therefore, the development of novel dual GLP-1/GIP agonists are a promising 
new development that may show even better protection than single incretin analogues. In diabetes 
drug research, novel dual agonists such as DA-JC1 have shown superior effects compared to 
lirglutide (Finan et al., 2013). We now have shown promising neuroprotective effects of DA-JC1 in 
two different animal models of PD (Cao et al., 2016; Ji et al., 2015). Newer dual agonists are 
currently being tested and directly compared with liraglutide, the currently best GLP-1 analogue on 
the market (Hölscher, 2016).  
As the GLP-1 mimetics exendin-4 and liraglutide are already on the market to treat diabetes, 
clinical trials have started that investigate the neuroprotective effects of exendin-4 or liraglutide in 
PD or AD patients. A pilot trial of exendin-4 in PD patients has shown good effects (clinical trials 
identifier NCT01174810). This ‘proof of concept’ study tested the effects of exendin-4 in an open 
label trial in 45 patients. When assessing motor activity in these patients, clear improvements had 
been observed, and even cognition was improved as measured by the specifically designed Mattis 
DRS-2 cognitive test. Patients were re-tested 12 months after the trial had finished, and the 
differences between groups in motor performance and cognitive scores had not changed (Aviles-
Olmos et al., 2014). This suggests that the group difference is not due to a placebo effect, as 12 
months is too long for such subjective effects to last. Based on these encouraging results, a phase II 
clinical trial that tested the once-weekly formulation of exendin-4, Bydureon®, has been completed 
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(NCT01971242). The results have not been published at this stage. A phase II trial testing 
liraglutide in PD patients has started in August 2016, testing patients in a double blind, placebo 
controlled design for one year.  
Clinical trials of novel dual GLP-1/GIP analogues in diabetes patients are ongoing, and the 
available data show that these drugs are effective and safe to take (Finan et al., 2013; Finan et al., 
2015). Once these drugs are licenced for use in patients, they can be fast-tracked into clinical trials 
in PD patients, with the hope of stopping disease progression in its tracks (Hölscher, 2016).  
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Fig. 1: Schematic diagram of the experimental design shows that rats received an injection of 
Desipramine and Pargyline 1 day prior to the surgery followed by a stereotaxic injection of 6-
OHDA or Saline in the MFB of right hemisphere. Six days later it was followed by daily injection 
of DA-JC1 i.p. (25nmol/kg body weight) for a total of 6 weeks. Amphetamine induced-circling 
tests were performed on the rats at 1 week and 5 weeks along with apomorphine induced 
contralateral rotational tests at 6 weeks. Rotarod was performed at 2 and 4 weeks and Open field 
test after 5 weeks. The rats were transcardially perfused using 4% Paraformaldehyde and the brains 
dissected out to be used for Immunohistochemistry and western blotting performed on lysate 
generated from striatum tissue dissected from non-perfused rats.  
 
Fig. 2: Body weight of animals of the three groups.  Treatment with 6-OHDA + saline or with 6-
OHDA + DA-JC1 did not affect body weight over time (two-way ANOVA). Error bars are SD, 
N=8 per group. 
 
Fig. 3: A. Amphetamine-induced circling. Animals received methamphetamine hydrochloride i.p. 
(3mg/kg body weight). After 30min of injection, the rats were placed in an open-field arena and 
their activity was recorded for 10 minutes. B. Apomorphine- induced circling. After 6 weeks of 
surgery the rats received subcutaneous injection of Apomorphine (Tocris), (0.05mg/kg body 
weight). 10min after injection the rats were placed in an open field and their activity was recorded 
for 45 minutes. Error bars are SD, N=8 per group. One-way ANOVA with Bonferroni post-hoc 
tests, ***=p < 0.001, *=p<0.05, ns: non-significant. 
 
Fig. 4: Rotarod performance. Animals were tested in the Rotarod at week 2 and 4 at two settings, 5-
45rpm increase over 200 sec (top) and 5-20rpm over 20 sec (bottom). The 6-OHDA lesion impaired 
animals in this motor competency task. DA-JC1 treatment improved the animals’ performance after 
the lesion. Performance at the 5-20rpm over 20 sec setting was not different to controls in the drug 
group. Error bars are SD, N=8 per group, ****=p < 0.0001, ***=p < 0.001, **=p<0.01, *=p<0.05, 
ns: non-significant. 
 
Fig. 5: Open field behavior. Grooming activity is reduced by the 6-OHDA lesion and normalised by 
DA-JC1 treatment. No effect was seen on rearing activity. The overall distance covered was 
reduced by the 6-OHDA lesion and normalised by DA-JC1. Sample tacks and a heat map of 
distribution of location is shown. Error bars are SD, N=8, *=p<0.05, ns: non-significant. 
 
Fig. 6: Histology of TH+ and GFAP positive neurons in the substantia nigra. A: When quantifying 
the tyrosine hydroxylase (TH) positive neurons that produce dopamine, it was found that the 6-
OHDA lesion reduced neuronal numbers. DA-JC1 protected neurons from the lesion. B: 
Inflammation was increased by 6-OHDA as shown be enhanced GFAP expression in astroglia. DA-
JC1 reduced the chronic inflammation. Error bars are SD. N=5 per group, ****=p < 0.0001, ***=p 
< 0.001, **=p<0.01, *=p<0.05, ns: non-significant. 
 
Fig. 7: Western blot analysis of key biomarkers in the brain (n=5). a. Ratio of pAkt 
(Ser473)/panAkt: There is a significant increase of 71.4% (p<0.01) in the pAkt (Ser473)/panAkt 
expression in the 6-OHDA + DA-JC1 treated group as compared to the 6-OHDA + saline treated 
group; b. Ratio of pCREB/Total CREB: DA-JC1 treatment increases pCREB expression by 2.2 fold 
and 2-fold when compared to the saline treated sham and 6-OHDA groups; c. Ratio of GDNF/beta-
actin: a 1.3-fold and 1.4-fold increase increase in GDNF expression in the 6-OHDA DA group as 
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compared to sham saline and 6-OHDA saline group; d. Ratio of Beclin/beta-actin: DA treatment 
enhances autophagy as evident from 1.54-fold and 1.5-fold increase in the Beclin- 1 expression in 
6-OHDA DA group as compared to the sham saline and 6-OHDA saline group, respectively. Error 
bars are STD. N=5 per group, ***=p < 0.001, **=p<0.01, *=p<0.05, ns: non-significant. 
 
Fig. 8: Dopamine content in the ipsilateral striatum of Sham Saline, 6-OHDA Saline and 6-OHDA 
+ DA-JC1 groups. Stereotaxic administration of 6-OHDA in the MFB of the right hemisphere 
resulted in a decrease of 52% in the dopamine levels in the striatum. This decrease was ameliorated 
by DA-JC1 treatment, which increased the dopamine content by 56% in the 6-OHDA + DA-JC1 
group as compared to the 6-OHDA saline treated group. Error bars are SD, N=6 per group. 
(****=p<0.0001, *=p<0.05, ns: non-significant).  
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